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Abstract
To increase the biocompatibility and durability of 
glutaraldehyde (GA)-fixed valves, a biological coat-
ing with viable endothelial cells (ECs) has been  
proposed. However, stable EC layers have not been  
formed successfully on GA-fixed valves due to their 
inability to repopulate. In this study, to improve 
cellular adhesion and proliferation, the GA-fixed  
prostheses were detoxified by treatment with citric  
acid to remove free aldehyde groups. Canine bone  
marrow mononuclear cells (MNCs) were differen -
tiated into EC-like cells and myofibroblast-like cells  
in vitro. Detoxified prostheses were seeded and  
recellularized with differentiated bone marrow- 
derived cells (BMCs) for seven days. Untreated  
GA-fixed prostheses were used as controls. Cell 
attachment, proliferation, metabolic activity, and  
viability were investigated and cell-seeded leaflets  
were histologically analyzed. On detoxified GA-fixed  
prostheses, BMC seeding resulted in uninhibited cell 
proliferation after seven days. In contrast, on  
untreated GA-fixed prostheses, cell attachment was  
poor and no viable cells were observed. Positive  
staining for smooth muscle α-actin, CD31, and  
proliferating cell nuclear antigen was observed on  
the luminal side of the detoxified valve leaflets, 
indicating differentiation and proliferation of the  
seeded BMCs. These results demonstrate that the  
treatment of GA-fixed valves with citric acid  
established a surface more suitable for cellular 
attachment and proliferation. Engineering heart 
valves by seeding detoxified GA-fixed biological 
valve prostheses with BMCs may increase  
biocompatibility and durability of the prostheses. 
This method could be utilized as a new approach  
for the restoration of heart valve structure and  
function in the treatment of end-stage heart valve  
disease.
Keywords: bone marrow cells; endothelial cells; 
heart valve prosthesis; tissue engineering
Introduction
Replacement of heart valves with mechanical or 
biological prostheses is currently a common treat-
ment for end-stage valvular diseases (Lupinetti et 
al., 1997). These heart valve prostheses substanti-
ally reduce the mortality of patients, but the pros-
theses have severe limitations. Mechanical valve 
prostheses are associated with a high incidence of 
thromboembolism due to their poor blood compati-
bility, and require long-term use of anti-clotting 
medication (Lupinetti et al., 1997). Biological tissue 
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valve prostheses, such as glutaraldehyde (GA)-fixed 
xenografts and cryopreserved homografts, suffer 
from limited durability and dysfunctions due to pro-
gressive tissue degeneration, and therefore may 
require successive surgery to replace the pros-
theses (Yacoub et al., 1995). The major disadvan-
tage of GA-fixed tissue valve prostheses is the 
degeneration of grafts, with subsequent calcification 
and tissue failure (Sodian et al., 2000). This may 
result from an inability of host cells to repopulate the 
valve due to the GA-fixation process (Yacoub et al., 
1995).
    Various strategies have been proposed to improve 
the performance of GA-fixed heart valve biopros-
theses (Moritz et al., 1990; Zilla et al., 1997; Wei-
ssenstein et al., 2000; Trantina-Yates et al., 2001; 
Gulbins et al., 2003). One method involves the use 
of a biological coating of viable endothelial cells 
(ECs) to increase the biocompatibility and durability 
of GA-fixed valves. By covering the surface of the 
valve prostheses with autologous ECs, valve de-
generation and thromboembolic events may be 
reduced. However, stable EC layers have not been 
formed successfully on GA-fixed valves due to their 
inability to be repopulated (Fischlein et al., 1992; 
Hoffmann et al., 1992; Bengtsson et al., 1993; 
Fischlein and Fasol, 1996). Methods that have 
previously been tested to improve cellular adhesion 
on GA-fixed prostheses include pretreatment of the 
prostheses with amino acid solutions (Fischlein et 
al., 1994) or citric acid solutions (Gulbins et al., 
2003), and precoating the valves with fibronectin or 
growth factors (Fischlein et al., 1994).
    The purpose of this study was to develop a 
detoxifying treatment method for GA-fixed prosthe-
ses that would enable seeded bone marrow-derived 
cells (BMCs) to cover the luminal surface of the 
prostheses. Canine BMCs were used as a cell 
source instead of vascular-derived ECs to overcome 
the problems of limited availability of intact vas-
culature and the invasiveness during cell harvest, 
which results in morbidity at the donor sites (Kadner 
et al., 2002). Seeding of BMCs on detoxified and 
untreated GA-fixed bioprosthetic tissues was investi-
gated in vitro. GA-fixed porcine pulmonary valves 
were treated with a detoxifying agent to establish a 
more suitable surface for BMC attachment and 
proliferation by removing cytotoxic free aldehydes. 
The detoxified prostheses were seeded and re-
cellularized in vitro with bone marrow-derived myo-
fibroblast (MF)-like cells and EC-like cells for seven 
days. The attachment, proliferation, metabolic acti-
vity, and viability of the seeded cells were investi-
gated and cell-seeded leaflets were histologically 
analyzed.
Materials and Methods 
Detoxification of glutaraldehyde-fixed porcine valves
Commercially available GA-fixed porcine mitral valve 
prostheses (model = 342R, size = 33 mm, Hancock 
Heart Valve, Medtronic Inc., Houston, TX) were 
rinsed three times with sterile distilled water and 
transferred to Medium 199 (M199, Gibco BRL, 
Gaithersburg, MD). Valves were incubated for 24 h 
at 4oC and then treated with 10% (w/v) citric acid 
solution (Sigma, St. Louis, MO) for 5 min to neu-
tralize the cytotoxic effect of free aldehydes (Gulbins 
et al., 2003). Residual reagents were removed by 
repeated washes in distilled water until neutral pH 
was achieved.
Culture of BMCs
Bone marrow (30 ml from each dog) was aspirated 
from the humeri of anesthetized mongrel dogs 
(20-25 kg) and immediately mixed with heparin (100 
unit heparin/ml bone marrow). The mixture was 
centrifuged on a Ficoll-Paque (Amersham Bioscien-
ce, Arlington Heights, IL) density gradient for 20 min 
at 1,500 rpm. Mononuclear cells were isolated from 
the buffy coat layer and washed three times in PBS 
(Sigma). The mononuclear cell fraction containing 
smooth muscle (SM) -actin-positive cells (MF-like 
cells) was cultured in M199 (Gibco BRL) containing 
10% (v/v) FBS (Gibco BRL) and 1% (v/v) penicillin 
and streptomycin (Gibco BRL). The mononuclear 
cell fraction containing CD31-positive cells (EC-like 
cells) was cultured in EGM-2 (Clonetics, San Diego, 
CA).
Characterization of BMCs
Cultured BMCs were stained immunochemically 
using antibodies against SM -actin (Clone 1A4, 
1:100 dilution) (Dako, Carpinteria, CA) and CD31 
(Clone JC/70A, 1:20 dilution) (Dako). Cultured cells 
were fixed with a 4% (v/v) paraformaldehyde solu-
tion for 30 min and permeabilized with 0.1% (v/v) 
Triton X-100 (Sigma) for 10 min. After treatment with 
3% (v/v) hydrogen peroxide (Sigma), cells were 
incubated at room temperature with primary anti-
bodies for two hours and with biotinylated anti- 
mouse IgG secondary antibody (Vector Laboratory, 
Burlingame, CA) for 30 min. Signals were developed 
using a streptavidin biotin universal detection system 
(UltraTech HRP, Immunotech, Marseille, France) and 
a 3,3'-diaminobenzidine tetrahydrochloride (DAB) 
substrate solution (Vector Laboratory).
Semi-quantitative reverse transcription (RT)-PCR
Total RNA was isolated from cultured EC-like cells 
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and MF-like cells using RNeasy Mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
protocol. cDNA was synthesized with 5 g of pure 
total RNA using SuperScriptTM II reverse trans-
criptase (Invitrogen Life Technologies, Carlsbad, CA) 
(Choi et al., 2004). cDNA was amplified with a 
thermal cycler (GeneAmp PCR System 2700, Appli-
ed Biosystems, Foster City, CA) using the primers in 
Table 1. PCR was performed for 30 cycles of de-
naturing (94oC, 30 s), annealing (60oC, 30 s), and 
extension (72oC, 45 s) with a final extension at 72oC 
for 7 min. PCR products were visualized by elec-
trophoresis on 2% (w/v) agarose gels containing 0.5 
g/ml ethidium bromide and analyzed with a gel 
documentation system (Gel Doc 1000, Bio-Rad La-
boratories, Hercules, CA).
Cell seeding and in vitro maintenance
Valves were sequentially seeded with MF-like cells 
(SM -actin-positive cells) followed by EC-like cells 
(CD31-positive cells). SM -actin-positive cells were 
uniformly seeded onto the valve leaflets at a cell 
density of 8.0 × 106 cells per prosthesis. Two hours 
later, CD31-positive cells were uniformly seeded 
onto the valve leaflets at a cell density of 2.0 × 106 
cells per prosthesis. Seeded valve prostheses were 
maintained in vitro in cell culture flasks (Bellco Glass 
Inc., Vineland, NJ) containing Medium 199 supple-
mented with 2% (v/v) FBS, human vascular endo-
thelial growth factor (10 ng/ml; PeproTech, Rocky Hill, 
NJ), and human basic fibroblast growth factor (2 ng/ml; 
PeproTech) for one week (Figure 1). Samples were 
taken one, four and seven days after cell seeding.
Table 1. Oligonucleotide primers used for RT-PCR and predicted product sizes.
Targets Sequences Product sizes (bp) References
eNOS F: 5 -TCA ACC AGT ACT ACA GCT CC-3
R: 5 -GTG GTT GCA GAT GTA GGT GA-3
251 Kalra et al., 2003
KDR F: 5 -TTC CTG ACC TTG GAG CAT CT-3
R: 5 -AGT CCA GCA TGG TCT GGT AC-3
430 Murata et al., 2000
SM -actin
F: 5 -GCC AAC CGG GAG AAA ATG AC-3
R: 5 -TCC TGT TTG CTG ATC CAC AT-3
743 Ishida et al., 2000
SM MHC F: 5 -CAG GGC AAC ATG GAG GC-3
R: 5 -GCC TCT TGA GCT GCT TGA CC-3
409 Ishida et al., 2000
Ribosome s17 F: 5 -GAA GGC GGC CCG GGT CAT CA-3
R: 5 -GTA GGC TGA GTG ACC TG-3
339 Ishida et al., 2000
Figure 1. BMC seeding on detoxified GA-fixed heart valve prostheses. (A) Gross view of cell-seeded heart valve prostheses. Tri-leaflets 
(asterisks) are observed. (B) Cell-seeded prostheses were maintained in vitro in cell culture flasks for seven days.
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Scanning electron microscopy
Scanning electron microscopy (SEM) of the valve 
leaflets was performed before and after cell seeding. 
Specimens were fixed, dehydrated and dried. Dried 
specimens were mounted on aluminum supports 
and coated with platinum using a Sputter Coater 
(Cressington Scientific Instruments Inc., Cranberry, PA). 
SEM (JEOL, Tokyo, Japan) was performed at 5 kV.
DNA quantification
To measure cell growth on the prostheses, the 
number of cells was determined by quantitative DNA 
assays performed in triplicate. DNA was isolated 
Figure 2. Characterization of cultured canine BMCs. BMCs cultured in EC culture condition showed the cobblestone morphology typical of ECs (A) 
and stained positively for CD31, a specific marker of ECs (B). BMCs cultured in MF cell culture condition had morphology similar to that of MFs (C) 
and stained positively for SM -actin, a specific marker of MF (D). (E) The mRNA expression of markers of ECs (eNOS and KDR) and markers of 
MFs (SM -actin and SM MHC) in BMCs cultured in EC-like and MF-like cell culture conditions. (F) Expression of each gene mRNA was normalized 
with house keeping Ribosomal s17 mRNA. The scale bars indicate 10 m. *P ＜ 0.05 compared with the other groups.
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using a Wizard Genomic DNA Purification kit (Pro-
mega, Madison, WI) according to the manufacturer’s 
protocol. DNA content was measured with an 
ultraviolet absorbance spectrophotometer (UV-160A 
spectrophotometer, Shimadzu, Kyoto, Japan) at 260 
nm. Cell numbers were calculated using a DNA 
standard curve for identical cells.
MTT assay
Mitochondrial metabolic activity of cells cultured on 
tissue culture plastics (TCP) and on GA-fixed pro-
stheses was measured in triplicate using the 3-(4,5- 
d imethylth iazol-2-y l) -2,5-d iphenyl- te trazol ium 
bromide) (MTT) assay (Liu et al., 2005). MTT stock 
solution (1 mg/ml; Sigma) was added to cultured 
cells and incubated at 37oC for 4 h. Following 
removal of the medium, formazan precipitates were 
solubilized by the addition of 1 ml 0.1N HCl solution 
containing 10% (w/v) sodium dodecyl sulfate and 
45% (w/v) dimethylformamide. Absorbance at 540 
nm was measured using a microplate reader 
(Multiskan Spectrum, Thermo Electron Co., Vantaa, 
Finland).
Cell viability assay
The viability of cells seeded on the GA-fixed pro-
stheses was measured by double staining using 
fluorescein diacetate (FDA, green fluorescence; 
Sigma) and ethidium bromide (EB, red fluorescence; 
Sigma) (Ryu et al., 2004). The staining solution was 
prepared by combining 10 ml of FDA solution (5 
mg/ml in acetone) and 5 ml of EB solution (10 g/ml 
in PBS). Samples were incubated in FDA/EB 
solution for 5 min at 37oC, washed twice in PBS, and 
observed under confocal microscopy (Fluoview 
BX50, Olympus, Tokyo, Japan).
Histological and immunohistochemical analyses
For histological analyses, specimens were fixed in 
10% (v/v) buffered formaldehyde and dehydrated 
with an ascending series of graded ethanol. Spe-
Figure 3. Scanning electron microscopy of 
prostheses. Scanning electron micrographs 
of the cell-seeded leaflets one day (A, C) 
and seven days (B, D) after cell seeding on 
detoxified (A, B) and untreated (C, D) 
GA-fixed prostheses. (E) Scanning electron 
micrographs of the GA-fixed leaflets without 
cell seeding. The scale bars indicate 20 m.
Figure 4. BMC proliferation on detoxified (solid circles) and untreated 
(open circles) GA-fixed prostheses. BMCs cultured on untreated pros-
theses showed decreased proliferation, while BMCs cultured on detoxi-
fied prostheses showed uninhibited proliferation. *P ＜ 0.05 compared 
with untreated group.
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cimens were embedded in paraffin, sectioned at 4 
m, and processed for hematoxylin and eosin (H&E) 
staining. For immunohistochemical analyses, 4 m- 
thick sections were stained using antibodies against 
CD31, SM -actin, and PCNA (Clone PC10, 1:200 
dilution; Dako). Sections were deparaffinized and 
incubated at room temperature with primary anti-
bodies for two hours and biotinylated anti-mouse IgG 
secondary antibodies for 30 min. Staining signals were 
developed using the streptavidin biotin universal 
detection system and DAB substrate solution.
Results
Differentiation and characterization of BMCs
Cultured canine BMCs were able to differentiate into 
EC-like cells and MF-like cells in vitro. BMCs grown 
in the EC culture condition showed the characteristic 
cobblestone morphology of ECs (Figure 2A) and 
Figure 5. Confocal microscopy 
of cell-seeded leaflets of detoxi-
fied (A, B) and untreated (C, D) 
GA-fixed prostheses stained with 
FDA and EB one day (A, C) and 
seven days (B, D) after cell 
seeding. Figure in the far left 
column indicate viable cells 
(green signals and figures in the 
middle column indicate dead 
cells (red signals), respectively. 
The scale bars indicate 20 m. 
All photographs were taken at 
the same magnification.
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stained positively for CD31, a marker of ECs (Figure 
2B). BMCs grown in the MF culture condition had 
morphology similar to MFs (Figure 2C) and express-
ed SM -actin, a marker of MFs (Figure 2D). The 
mRNA markers of ECs, endothelial nitric oxide 
synthase (eNOS) and kinase-insert domain-contain-
ing receptor (KDR), were expressed at a higher 
extent in the BMCs cultured in the EC-like cell 
culture condition than freshly isolated bone marrow 
MNCs and cells cultured in the MF-like cell culture 
condition. The mRNA markers of MFs, SM -actin 
and SM myosin heavy chain (MHC), were expressed 
at a higher extent in BMCs cultured in the MF-like 
cell culture condition than freshly isolated bone 
marrow MNCs and cells cultured in the EC-like cell 
culture condition (Figure 2E and F). 
Seeding on GA-fixed prostheses
GA-fixed valve prostheses, with or without detoxi-
fying treatment, were seeded with EC-like cells and 
MF-like cells differentiated from bone marrow MNCs, 
and maintained in vitro for one week. Pretreatment 
of GA-fixed prostheses with 10% (w/v) citric acid 
improved the efficiency of BMC seeding. SEM analy-
sis showed that BMC seeding on detoxified GA-fixed 
valves resulted in even cell attachment one day after 
seeding (Figure 3A) and formation of a confluent 
layer of cells over the surface of the valve leaflets 
after one week (Figure 3B). In contrast, BMC 
seeding on untreated GA-fixed valves resulted in 
scattered BMCs on the surface one day after 
seeding (Figure 3C) and disappearance of these 
cells after seven days (Figure 3D).
Cell proliferation on GA-fixed prostheses
Detoxified GA-fixed prostheses allowed adhesion 
and proliferation of seeded BMCs over a culture 
period of seven days. The initial cell seeding density 
of 3.0 × 105 cells/cm2 resulted in 1.1 × 105 cells/cm2 
remaining attached to the detoxified GA-fixed valve 
after one day in culture, an adhesion percentage of 
36.7% (Figure 4). For the untreated GA-fixed valve, 
the cell adhesion efficiency was 17.2%. Seeded 
BMCs also grew more rapidly in the detoxified 
GA-fixed valve than in the untreated GA-fixed valve. 
After seven days in culture, the average cell density 
of the detoxified GA-fixed valve was 3.7 × 105 
cells/cm2, while that of the untreated GA-fixed valve 
was 0.1 × 105 cells/cm2, corresponding to a 236% 
increase and 90.9% decrease in cell density 
compared to the initial cell adhesion densities for the 
detoxified and untreated GA-fixed valves, respec-
tively (Figure 4).
Cell viability on GA-fixed prostheses
Viability of BMCs seeded on GA-fixed prostheses 
was examined by fluorescent microscopy with 
differential staining for viable and nonviable cells: 
FDA stains the cytoplasm of viable cells green and 
EB stains the nuclei of nonviable cells orange-red. 
Confluent viable cells were present on the surface of 
detoxified GA-fixed prostheses one day after seed-
ing (Figure 5A). Most of the cells showed FDA- 
positive staining (green fluorescence) seven days 
after cell seeding, indicating that they remained 
viable during the in vitro culture periods (Figure 5B). 
In contrast, cell viability decreased over time on 
untreated GA-fixed prostheses. One day after seed-
ing on untreated valves, more than half of the cells 
Figure 6. MTT staining of BMCs seeded on detoxified (A) and untreated (B) GA-fixed prostheses seven days after cell seeding. Formation of for-
mazan precipitates was observed on detoxified prostheses (A), but not on untreated prostheses (B). (C) Metabolic activity of BMCs cultured on TCP 
(solid circles), detoxified (open circles), and untreated (solid inverted triangles) GA-fixed prostheses. *P ＜ 0.05 compared with TCP.
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stained with EB (red) and only a few cells showed 
FDA-positive staining, indicating few viable cells on 
the surface (Figure 5C). After seven days no viable 
cells were found on the untreated GA-fixed pros-
theses and all of the cells showed EB-positive 
staining (Figure 5D). 
MTT assay
The MTT cytotoxicity assay showed the effect of the 
detoxifying treatment on the relative survival of 
BMCs on the GA-fixed valves, as measured by 
metabolic activity. BMCs cultured on detoxified pros-
theses showed a similar metabolic activity to those 
cultured on TCP, while BMCs cultured on untreated 
prostheses showed significantly reduced metabolic 
activity (Figure 6). These results verify the cytoco-
mpatibility of the detoxified GA-fixed prostheses. Cell 
survival and metabolic activity remain high on the 
detoxified GA-fixed prostheses for up to seven days 
after seeding.
Histological and immunohistochemical analyses
H&E staining of the valves one day after cell seeding 
showed that a high density of cells was present on 
the leaflets of the detoxified prostheses (Figure 7B), 
while only scattered BMCs were present on the 
leaflets of untreated prostheses (Figure 7D). Seven 
days after seeding, a stable and confluent cell layer 
was achieved on the detoxified prostheses (Figure 
7C), but no cells were observed on the surface of 
the leaflets of the untreated prostheses (Figure 7E).
    The cells lining the leaflet surfaces of detoxified 
GA-fixed valves stained positively for PCNA, a 
marker of proliferating cells, at seven days after in 
vitro culture (Figure 8A). PCNA positive cells were 
only observed on the leaflet surfaces and not in the 
Figure 8. Immunohistochemical analysis of BMC-seeded detoxified prostheses seven days after cell seeding: (A) PCNA; (B) SM -actin; (C) CD31. 
The scale bars indicate 20 m.
Figure 7. H&E staining of leaflets of un-
seeded GA-fixed prostheses (A) and BMC- 
seeded prostheses (B-E) one day (B, D) and 
seven days (C, E) after cell seeding on de-
toxified (B, C) and untreated (D, E) pro-
stheses. The scale bars indicate 20 m.
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interstitial region. The cells on the leaflet surfaces 
also stained positively for SM -actin, a MF marker, 
(Figure 8B) and for CD31, an EC marker (Figure 
8C). However, positive staining for PCNA, CD31, 
and SM -actin was not observed on the surface of 
untreated GA-fixed prostheses at seven days after 
seeding.
Discussion
Successful engineering of heart valve tissue re-
quires a safe and reliable scaffold. Although GA- 
fixed valve prostheses have the disadvantage of 
cytotoxicity due to the fixation procedure, we used 
these prostheses as scaffolds for heart valve tissue 
engineering for the following reasons. The manufac-
turing process of these prostheses has been stan-
dardized; cross-linking by GA-fixation reduces im-
munogenicity; and the fixation process facilitates 
good mechanical properties and surgical handling 
(Gulbins et al., 2003). Therefore, these prostheses 
have several potential advantages as tissue engi-
neering scaffolds which could be applied for clinical 
use in the future.
    Several groups have studied seeding of human 
ECs on biological valve prostheses. However, 
seeding on GA-fixed valves has yielded poor results, 
mainly due to continual release of toxic GA and 
remaining free aldehyde groups (Fischlein et al., 
1992; Hoffmann et al., 1992; Bengtsson et al., 1993; 
Fischlein and Fasol, 1996). In the present study, the 
initial seeding of BMCs on extensively rinsed 
untreated prostheses was successful, but the cells 
rapidly lost adhesion and did not survive seven days. 
The cytotoxicity of GA-fixed valves was significantly 
reduced by pre-incubation in cell culture medium 
and citric acid solution. During the GA-fixation 
process, GA covalently cross-links collagen fibers 
through the amino groups of the proteins, resulting in 
reduced immunogenicity and improved mechanical 
properties relative to fresh porcine aortic valves 
(Gulbins et al., 2003). After fixation, unbound GA can 
be washed out by rinsing with cell culture medium, 
but GA covalently bounded with collagen fibers can 
not simply be washed out, and the free aldehyde 
groups of this remaining GA causes cytotoxicity. The 
cross-linking of collagen fibers by GA-fixation also 
results in a hydrophobic surface, thus reducing the 
capability of cells to adhere, since cells attaching 
through pseudopodia that use non-covalent bonds 
require a hydrophilic surface (Gulbins et al., 2003). 
This hydrophobicity, combined with the toxicity of 
free aldehyde groups, results in poor adhesion and 
cell viability.
    Our studies show that pretreatment with citric acid 
increased both cell adhesion and viability following 
seeding with BMCs. Citric acid reacts with free 
aldehyde groups, thus reducing cytotoxicity (Gulbins 
et al., 2003). In addition, citric acid is a strong 
organic acid that binds to amino groups of the 
collagen fibers, increasing the hydrophilicity of the 
surface and enhancing cellular attachment (Gulbins 
et al., 2003). Therefore, the detoxification treatment 
changed the surface properties of the prostheses to 
improve cellular adhesion.
    Establishing a reliable cell source is also vital for 
the successful tissue engineering of heart valves. 
Various cell types have been used, including dermal 
fibroblasts (Shinoka et al., 1997), vascular-derived 
cells (Hoerstrup et al., 2000; Sodian et al., 2000), 
and mesenchymal stem cells from bone marrow 
(Hoerstrup et al., 2002; Kadner et al., 2002; Perry et 
al., 2003a; Perry and Roth, 2003b). However, dermal 
fibroblasts resulted in contracted and immobile 
leaflets (Shinoka et al., 1997). Vascular-derived cells 
are the most frequently used and have produced 
positive results in previous attempts to fabricate 
tissue engineered heart valves (Hoerstrup et al., 
2000). However, this requires the sacrifice of intact 
tissues and additional invasive surgery to harvest 
cells. In addition, the characteristics of vascular- 
derived cells are different from those of valvular 
cells, which may affect the function of tissue-engi-
neered heart valves (Flanagan and Pandit, 2003). 
    BMCs are an attractive source of cells for the 
development of tissue-engineered heart valves that 
may overcome the limitations of other cell sources. 
Bone marrow aspiration is less invasive, and cell 
isolation is associated with much lower morbidity at 
the donor sites, than blood vessel biopsy (Kadner et 
al., 2002). Using patients’ own BMCs, autologous 
valvular grafts could be constructed that may avoid 
immune rejection. Recently, a clinical case report 
demonstrated the feasibility of tissue engineering of 
human blood vessels with autologous bone marrow 
MNCs (Matsumura et al., 2003). In addition, cell 
therapy using autologous bone marrow MNCs or 
bone marrow AC133-positive cells has been clini-
cally tested in humans for neovascularization in limb 
ischemia (Tateishi-Yuyama et al., 2002) or infarcted 
myocardium (Stamm et al., 2003). These results 
demonstrate the applicability of BMCs as an auto-
logous cell source in the clinical treatment of car-
diovascular diseases. We have previously reported 
the tissue engineering of small-diameter blood ve-
ssels and vascular smooth muscles using BMCs 
(Cho et al., 2004; 2005a; b), and several studies 
have used the bone marrow as a cell source for the 
tissue engineering of heart valves (Hoerstrup et al., 
2002; Kadner et al., 2002; Perry et al., 2003a). In the 
present study, the potential of BMCs to differentiate 
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into valvular cells has been shown, and the ap-
plicability of BMCs for the construction of tissue- 
engineered heart valves was verified. We have iden-
tified culture conditions that allow for the proliferation 
and differentiation of the multiple cell types ne-
cessary for valvular tissue regeneration. Genetic and 
immunochemical characterization demonstrated that 
cultured BMCs could differentiate into EC-like cells 
and MF-like cells by exposure to the appropriate 
culture conditions.
    In summary, this study demonstrated the tissue 
engineering of biological valvular prostheses in vitro 
using detoxified GA-fixed prostheses and BMCs. 
The heart valves engineered with valvular cells 
induced from BMCs showed tissue regeneration with 
a CD31-positive layer. Before such recellularized 
valves can be used in clinical procedures, in vivo 
experiments are necessary to prove whether the 
seeded BMC layer improves biocompatibility and 
durability of the GA-fixed valve prostheses. Because 
physical stress on the valvular structures plays an 
important role in bioprosthetic degeneration, a large 
animal model such as an ovine model should be 
used to test the valves under physiological con-
ditions. In addition, the method of cell seeding on 
prostheses needs to be further improved. Although 
the detoxified prostheses demonstrate improved 
biocompatibility, the initial cell adhesion ratio is low. 
This may be due to the immediate detachment of 
BMCs from the leaflets after cell seeding. It is 
possible that cell seeding and in vitro maintenance 
in a static culture condition is inefficient, and that 
dynamic cell seeding (Kim et al., 1998) and pre-
conditioning of the seeded prostheses in a pulsatile 
bioreactor might improve cell adhesion ratio and 
tissue regeneration. Further characterization of val-
vular cells differentiated from bone marrow MNCs is 
also necessary, and additional studies related to the 
growth, remodeling, durability, calcification and func-
tion of tissue-engineered heart valves with respect to 
long-term implantation are required.
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